WO2009046877A3 - Use of a histrelin and leuprolide as therapeutic agents - Google Patents

Use of a histrelin and leuprolide as therapeutic agents Download PDF

Info

Publication number
WO2009046877A3
WO2009046877A3 PCT/EP2008/008144 EP2008008144W WO2009046877A3 WO 2009046877 A3 WO2009046877 A3 WO 2009046877A3 EP 2008008144 W EP2008008144 W EP 2008008144W WO 2009046877 A3 WO2009046877 A3 WO 2009046877A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
leu
histrelin
leuprolide
therapeutic agents
Prior art date
Application number
PCT/EP2008/008144
Other languages
French (fr)
Other versions
WO2009046877A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Lab Ag
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Lab Ag, Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher filed Critical Mondobiotech Lab Ag
Publication of WO2009046877A2 publication Critical patent/WO2009046877A2/en
Publication of WO2009046877A3 publication Critical patent/WO2009046877A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention is directed to the use of the combination of the peptide compounds Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt and Pyr-D-His-Trp- Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008144 2007-09-11 2008-09-09 Use of a histrelin and leuprolide as therapeutic agents WO2009046877A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPEP07017751.4 2007-09-11
EP07017751 2007-09-11
EPEP07017754.8 2007-09-11
EP07017754 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009046877A2 WO2009046877A2 (en) 2009-04-16
WO2009046877A3 true WO2009046877A3 (en) 2009-05-28

Family

ID=40456203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008144 WO2009046877A2 (en) 2007-09-11 2008-09-09 Use of a histrelin and leuprolide as therapeutic agents

Country Status (1)

Country Link
WO (1) WO2009046877A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
WO2002030351A2 (en) * 2000-10-13 2002-04-18 Monash University Improvement of graft acceptance through manipulation of thymic regeneration
US20060188521A1 (en) * 2000-10-13 2006-08-24 Monash University Treatment of T cell disorders
WO2006119388A2 (en) * 2005-05-03 2006-11-09 Novetide, Ltd. Methods for the production of peptide having a c-terminal amide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
WO2002030351A2 (en) * 2000-10-13 2002-04-18 Monash University Improvement of graft acceptance through manipulation of thymic regeneration
US20060188521A1 (en) * 2000-10-13 2006-08-24 Monash University Treatment of T cell disorders
WO2006119388A2 (en) * 2005-05-03 2006-11-09 Novetide, Ltd. Methods for the production of peptide having a c-terminal amide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARBIERI ET AL: "Clinical applications of GnRH and its analogues", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 3, no. 1, 1 January 1992 (1992-01-01), pages 30 - 34, XP023117883, ISSN: 1043-2760, [retrieved on 19920101] *
CHERTIN ET AL: "AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 163, no. 3, 1 March 2000 (2000-03-01), pages 838 - 844, XP005555991, ISSN: 0022-5347 *
FOWLER ET AL: "SAFETY AND EFFICACY OF AN IMPLANTABLE LEUPROLIDE DELIVERY SYSTEM IN PATIENTS WITH ADVANCED PROSTATE CANCER", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 164, no. 3, 1 September 2000 (2000-09-01), pages 730 - 734, XP005553661, ISSN: 0022-5347 *
HISTRELIN STUDY GROUP ET AL: "Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 175, no. 4, 1 April 2006 (2006-04-01), pages 1353 - 1358, XP024990022, ISSN: 0022-5347, [retrieved on 20060401] *

Also Published As

Publication number Publication date
WO2009046877A2 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009043522A3 (en) Use of a peptide as a therapeutic agent
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
HK1110526A1 (en) Medicaments for the treatment or prevention of fibrotic diseases
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2004091490A3 (en) Somatostatin-dopamine chimeric analogs
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent
WO2009043523A3 (en) Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
EP3658157A4 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2009046877A3 (en) Use of a histrelin and leuprolide as therapeutic agents
WO2009046872A3 (en) Use of a peptide as a therapeutic agent
WO2009046880A3 (en) Use of a peptide as a therapeutic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802612

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802612

Country of ref document: EP

Kind code of ref document: A2